Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations



Home | Modify Search


Search Results for Proprietary Name, Active Ingredient or Application Number: 007517



Home | Back to Search Results

Product Details for NDA 007517

Expand all




Home | Back to Product Details

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
 Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N007517



Home | Back to Search Results

Product Details for NDA 007517

Expand all

TAPAZOLE (METHIMAZOLE)
5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Marketing Status: Discontinued TAPAZOLE (METHIMAZOLE) 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Marketing Status: Discontinued Active Ingredient: METHIMAZOLE
Proprietary Name: TAPAZOLE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number 1997/177 Application Number: N007517 Product Number: 004 Approval Date: Approved Prior to Jan 1, 1982
Applicant Holder Full Name: KING PHARMACEUTICALS INC Marketing Status: Discontinued
Patent and Exclusivity Information

Home | Back to Product Details

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
 Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
 As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N007517

